BACKGROUND/OBJECTIVES: Glycogen storage disease type I (GSD I) is an autosomal recessive metabolic disorder caused by defects in the glucose-6-phosphatase complex. Deficient activity in the glucose-6-phosphatase-a catalytic unit characterizes GSD Ia and defects in the glucose-6-phosphate transporter protein characterize GSD Ib. Type Ia involves the liver, kidney and intestine (and Ib also leukocytes), and the clinical manifestations are hepatomegaly, failure to thrive, severe fasting hypoglycemia within 3-4 h after a meal, hyperlactatemia, hyperuricemia and hyperlipidemia. The aim of the present study was to examine the safety and efficacy of a continuous subcutaneous glucose monitoring system to determine the magnitude and significance of hypoglycemia in GSD I and to evaluate the efficacy of the revised dietary treatment. SUBJECTS/METHODS: Sixteen children with GSD I were studied over a 72-h period. Continuous glucose monitoring (CGM) was repeated in all patients 3-6 months after the first monitoring to examine the effects of revised dietary instructions on glycemic control. RESULTS: All the patients completed the study without any major adverse events. Significant periods of asymptomatic hypoglycemia (below 4 mmol/l, 70 mg/dl) were noted. There was a close correlation between CGM sensor and capillary blood glucose values measured by a glucometer. CGM indicated a considerable reduction in duration of hypoglycemia, liver size and improvements in secondary metabolic derangements such as hyperlacticacidemia and hyperlipidemia. CONCLUSIONS: CGM could be applied in the clinical setting to help the physician to identify hypoglycemic events, and repeated CGM may serve as a safe and useful tool for the assessment of the long-term management of patients with GSD I.
INTRODUCTION
Glycogen storage disease type I (GSD I), characterized by impaired production of glucose from glycogenolysis and gluconeogenesis, results from defects in the glucose 6-phosphate enzyme system. Glucose-6-phosphatase is affected in GSD Ia, whereas GSD Ib results from a defect of the G6P transporter, G6P translocase. Type Ia involves the liver, kidney and intestine (and Ib also leukocytes), and the clinical manifestations are hepatomegaly, failure to thrive, severe fasting hypoglycemia within 3-4 h after a meal, hyperlactatemia, hyperuricemia and hyperlipidemia. Management of the GSD I is primarily dietary and is aimed at maintaining euglycaemia. 1, 2 Since the late 1970 s, self-monitoring of blood glucose (SMBG) has been the standard for assessing daily glycemic control. 3 The first continuous glucose monitoring system (CGMS) became available in 1999. Numerous clinical trials have documented the benefits of continuous glucose monitoring (CGM) in patients with diabetes mellitus. However, the data supporting the use of CGM in GSD type I patients are less substantial. [4] [5] [6] Real-time glucose monitoring device provides glucose measurements every 5 min, producing 288 measurements per day, consists of a disposable transcutaneous glucose sensor connected to a transmitter and a receiver. The receiver has a screen that displays the glucose level together with graphic representations of the glucose patterns. Medtronic real-time continuous glucose monitoring device also has adjustable alarms for high and low glucose levels. The system is calibrated using fingerstick blood glucose measurements. 7, 8 Continuous glucose monitors (CGMs), devices that can measure interstitial glucose in 'real time,' have become widely available particularly for use in patients with diabetes, and their accuracy and ease of use have greatly improved over the last decade. 9, 10 The aim of the present study was to examine the safety of a continuous subcutaneous glucose monitoring system, to determine the magnitude and significance of hypoglycemia in GSD I and to evaluate the efficacy of the revised dietary treatment.
MATERIALS AND METHODS
Medtronic real-time continuous glucose monitoring device was used in the current study. CGM provides moment-to-moment tracking of glucose concentrations and measures of intra-and interday variability over a 72-h period, which are particularly salient measures in children with GSD I. Sixteen patients with GSD I (15 GSD Ia, 1 GSD Ib) were enrolled between April 2011 and January 2012. In order to be eligible for this study, children were required to be between the ages 2-18 years, have been diagnosed with GSD I, and must have used dietary treatment for a minimum of 1 year and willingness to wear a medical device for 72 consecutive hours.
The study protocol was approved by the ethics committee of our hospital, and informed consent was obtained from the participants and parents of the minors (under 18 years of age) before enrollment.
After recruitment, a Minimed sensor was placed by securing a sterile field in the lower abdomen, hip or buttock area and inserting the needle using a spring loaded insertion device in the subcutaneous tissue, covering the insertion point with a minimal amount of transparent adhesive dressing ( Figure 1 ). CGM sensor insertion occured in the pediatric metabolic clinic and was performed by trained study personel. It was then connected to the CGMS. The sensor is coated with glucose oxidase, and, in the presence of glucose in the interstitial space, it generates an electric current that is transmitted and stored in the monitor every 10 s. The system is designed to measure blood glucose levels in a range of 40-400 mg/dl (Figure 2 ). The monitor calculates the average measurement every 5 min using a computer-driven algorithm, and the sensors relate the subcutaneous interstitial fluid glucose measurements to capillary BG concentrations. Registered values can be downloaded onto a computer after the sensor is removed and managed with the corresponding software. The sensor requires at least two capillary glucose readings each day (every 12 h) to validate sensor function and allow for the development of a calibration equation. Parents and doctors were provided brief training. Sixteen children ( 9 boys and 7 girls) with GSD I were studied over a 72-h period. We have investigated 15 patients with GSD Ia, one patient with GSD Ib with continuous glucose monitoring. The patients and doctors were not aware of the sensor recordings during the time of glucose monitoring. Capillary blood glucose was measured several times before meals and snacks during this time by the parents or doctors using a glucometer, which reliably detects blood samples. Because of many factors, including pain and inconvenience, eight-point fingerstick measurements (selfmonitoring of blood glucose) per day were done by 3 days during continuous glucose monitoring system. CGM was repeated 3-6 months after the first monitoring in all patients to examine the effects of revised dietary instructions on glycemic control. Blood lactate, triglyceride, total cholesterol, aspartate aminotransferase and alanine aminotransferase levels and blood gas analysis were measured at the start and after 3-6 months of the study. Adverse events including infection, bleeding, allergic reaction, device failure and sensor dislodgement were recorded during CGMS-wearing periods. More uncooked cornstarch was added to the diet of patients, and glucose intake was increased according to first CGM glucose concentrations and altered the time interval between meals.
Statistical analysis
Statistical analyses were performed using the SPSS software version 15. The variables were investigated using visual (histograms, probability plots) and analytical methods (Kolmogorov-Smirnov/Shapiro-Wilk's test) to determine whether or not they are normally distributed. While investigating the associations between non-normally distributed and/or ordinal variables, the correlation coefficients and their significance were calculated using the Spearman test. Agreement between the paired measurements obtained by the two different systems was also assessed by the BlandAltman method. All tests were considered significant for P-values o0.05.
RESULTS
Mean age of the study population was 7.59± 4.12 years (range 2-18). Demographic data are summarized in Table 1 . During the study, the patients followed a normo-caloric diet suggested by the registered dietician with a distribution of nutrients as recommended for patients with GSD I (57-64% carbohydrates, 25-29% lipids, 10-16% proteins). All the patients completed the study without any major adverse events. None of the patients experienced infection at the insertion site. Psychological aversion and discomfort related to sensor/adhesive tape were not observed in this population. There were only minor local adverse events: redness, hypersensitivity and minor subcutaneous hemorrhage. The sensor function measured according to electrical signals failed (always on day 1) in four cases (25%). None of these resulted in sensor withdrawal. In 11 volunteers (68%), no complications were observed ( Table 2 ). All patients fully completed the CGMS. Significant periods of asymptomatic hypoglycemia (below 4 mmol/l, 70 mg/dl) were noted. There was a close correlation between CGM sensor and capillary blood glucose values measured by a glucometer before and after diet revision. In this study, a total of 768 FSBG readings were collected that had Figure 2 . Glucose profiles of a participant with GSD Ia before intervention revealing multiple episodes of recurrent hypoglycemia (o70 mg/dl). (Figures 3 and 4) . The correlation remained excellent with a mean glucose difference of 4 mg/dl between methods (Figures 5 and 6 ). CGM indicated a considerable reduction in liver size and duration of hypoglycemia, which dropped from 7.06±5.04% to 2.25±2.79% (Po0.001, P ¼ 0.002), and statistically significant improvements in secondary metabolic derangements such as hyperlacticacidemia, hypertriglyceridemia, aspartate aminotransferase and alanine aminotransferase levels (Po0.05) ( Table 3 ). The CGMS shown to be a very safe and efficacious method, well tolerated, with high accuracy in glycemic values and low complications rate.
DISCUSSION
This is a clinical trial evaluating the use of CGMS in children with GSD I. In GSD I, the lack of enzyme glucose-6-phosphatase or translocase results in repeated asymptomatic hypoglycemia episodes, increased production in lactic acid, triglyceride and uric acid as a consequence of the impaired production of glucose from glycogenolysis and gluconeogenesis. From our experience CGM, in combination with other appropriate biochemical monitoring and dietary intake records, has been shown to be a useful tool in the practical management of GSD and is consistent with the few studies previously reported. In 2001, Hershkovitz et al. 5 examined the efficacy of CGMS MiniMed, determined the magnitude and significance of hypoglycemia in four patients with GSD I and evaluated the efficacy of its dietary treatment. Results of the study indicated that CGMS values were highly correlated with paired blood glucose values measured by a glucometer, and significant periods of asymptomatic hypoglycemia were noted. This study was the first to report the use of CGMS in GSD patients. In 2004, Maran et al. 9 have investigated four patients with GSD Ia, one patient with GSD Ib and one patient with GSD III, aged between 11-47 years with 48 h of continuous glucose monitoring and revealed unrecognized episodes of hypoglycemia in four out of six patients. Maran et al. 9 were the second to report the use of CGMS in GSD patients. In 2011, White et al. 11 have shown that the use of CGM, combined as appropriate with lactate and/or ketone Figure 3 . Correlation between the medtronic CGM and standard glucometer glucose concentration in the whole population under study before diet modification (correlation is significant at the P ¼ 0.01 level). Figure 4 . Correlation between the medtronic CGM and standard glucometer glucose concentration in the whole population under study after diet modification (correlation is significant at the P ¼ 0.01 level). measurements, and subsequent management changes have lead to improved biochemical control in patients with GSD. They emphasized that CGM is a reliable, well accepted and valid tool in the monitoring of GSD patients. The encouraging results of these studies led us to design the current prospective clinical trial. [11] [12] [13] [14] In this trial, the primary outcome was improvement in GSD control according to our results that continuous glucose monitoring was found to be associated with reduced time spent in hypoglycemia and a concomittant decrease in liver size by clinical examination, lactate, aspartate aminotransferase, alanine aminotransferase and triglyceride concentrations in children with GSD I (Po0.05).
The activation of the autonomic response and glucagon release when blood glucose falls below 4 mmol/l induces secondary metabolic derangements such as hyperlacticacidemia, hyperlipidemia and hyperuricemia. When hypoglycemia is prevented by providing an appropriate amount of glucose throughout the day and night to GSD I patients, the biochemical abnormalities are ameliorated and liver size decreases. Responses from families have been uniformly positive for its use. Reliability of readings were very good in the current study.
Continuous Glucose Monitoring (CGM) is a developing technology in the field of diabetes treatment. Over the last years, continuous glucose monitoring systems (CGMS) have become a very useful tool for the treatment of type 1 diabetes (T1D), and several studies have shown their utility in lowering hemoglobin A1c and reducing glycemic variability. [12] [13] [14] [15] In conclusison, this trial is the largest report of continuous subcutaneous glucose monitoring in children with GSD I and demonstrated the place of repeated CGM as a tool for improving biochemical parameters and glycemic status following dietary modifications. Given our results and those of previous studies, we expect CGMS monitoring to become an important adjuvant to self-monitoring of blood glucose in the treatment of GSD I. The device provides a more complete picture of blood glucose excursions and glycemic trends, allowing the careprovider and patient to make better informed management decisions. We are a proponent of intermittent CGMS use in patients with GSD I, particularly in those with poor metabolic control, known or suspected recurrent severe hypoglycemia.
In conclusion, use of CGMS in children with GSD I appears to be a safe, efficacious and very good reliable method to identify asymptomatic hypoglycemia and to improve metabolic changes in therapeutics with significant impact in lactate, triglyceride, aspartate aminotransferase, alanine aminotransferase and glucose values of pediatric GSD I. However, the long-term benefits on metabolic control remain to be determined. 
